Status:
ACTIVE_NOT_RECRUITING
SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers
Lead Sponsor:
University of Patras
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function. The study enrolls type 2 diabetic patients in whom the i...
Eligibility Criteria
Inclusion
- type 2 diabetes
- Hba1C\>7% on their current treatment
- introduction of SGLT2 inhibitor as part of their routine care
Exclusion
- eGFR\<60 ml/min
Key Trial Info
Start Date :
June 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05408936
Start Date
June 3 2022
End Date
June 1 2024
Last Update
May 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Patras
Pátrai, Greece, 26504